Adhoute Xavier, Penaranda Guillaume, Castellani Paul, Perrier Herve, Bourliere Marc
Xavier Adhoute, Paul Castellani, Herve Perrier, Marc Bourliere, Department of Hepatology, Hopital Saint-Joseph, 13285 Marseille, France.
World J Hepatol. 2015 Mar 27;7(3):521-31. doi: 10.4254/wjh.v7.i3.521.
Several hepatocellular carcinoma (HCC) staging systems have been established, and a variety of country-specific treatment strategies are also proposed. The barcelona - clinic liver cancer (BCLC) system is the most widely used in Europe. The Hong Kong liver Cancer is a new prognostic staging system; it might become the reference system in Asia. Transarterial chemoembolization (TACE) is the most widely used treatment for HCC worldwide; but it showed a benefit only for intermediate stage HCC (BCLC B), and there is still no consensus concerning treatment methods and treatment strategies. In view of the highly diverse nature of HCC and practices, a scoring system designed to assist with decision making before the first TACE is performed or prior to repeating the procedure would be highly useful.
已经建立了几种肝细胞癌（HCC）分期系统，并且还提出了各种针对特定国家的治疗策略。巴塞罗那临床肝癌（BCLC）系统在欧洲使用最为广泛。香港肝癌是一种新的预后分期系统；它可能会成为亚洲的参考系统。经动脉化疗栓塞术（TACE）是全球范围内治疗HCC应用最广泛的方法；但它仅对中期HCC（BCLC B期）显示出益处，并且在治疗方法和治疗策略方面仍未达成共识。鉴于HCC及其治疗方法的高度多样性，设计一种评分系统以在首次进行TACE之前或重复该程序之前辅助决策将非常有用。
